New drug aims to boost immune cells in rare blood disorder
Disease control
Recruiting now
This Phase 3 study tests whether the drug mavorixafor can reduce serious infections and increase neutrophil levels in people with chronic neutropenia—a condition where the body doesn't make enough infection-fighting white blood cells. About 176 participants will receive either ma…
Phase: PHASE3 • Sponsor: X4 Pharmaceuticals • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC